Honggui Li Selected Research

Phosphofructokinase-2 (Phosphofructokinase 2)

1/2021	Adipocyte inducible 6-phosphofructo-2-kinase suppresses adipose tissue inflammation and promotes macrophage anti-inflammatory activation.
4/2016	PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs.
1/2016	Glucose and Palmitate Differentially Regulate PFKFB3/iPFK2 and Inflammatory Responses in Mouse Intestinal Epithelial Cells.
6/2012	Targeted overexpression of inducible 6-phosphofructo-2-kinase in adipose tissue increases fat deposition but protects against diet-induced insulin resistance and inflammatory responses.
2/2010	Disruption of inducible 6-phosphofructo-2-kinase ameliorates diet-induced adiposity but exacerbates systemic insulin resistance and adipose tissue inflammatory response.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Honggui Li Research Topics

Disease

16	Inflammation (Inflammations) 01/2022 - 06/2012
12	Insulin Resistance 01/2021 - 09/2006
8	Non-alcoholic Fatty Liver Disease 01/2022 - 01/2012
7	Obesity 01/2022 - 12/2012
2	Weight Loss (Weight Reduction) 01/2022 - 09/2019
2	Bites and Stings (Sting) 12/2018 - 01/2017
2	Neoplasms (Cancer) 04/2016 - 01/2004
2	Carcinogenesis 04/2016 - 01/2004
2	Overnutrition 05/2013 - 04/2013
2	Hyperglycemia 07/2010 - 09/2006
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022
1	Alcoholic Fatty Liver 01/2022
1	Ear Diseases (Disease, Ear) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Ischemia 01/2018
1	Metabolic Diseases (Metabolic Disease) 01/2017
1	Glucose Intolerance 07/2010
1	Body Weight (Weight, Body) 08/2005
1	Neuroectodermal Tumors (Neuroectodermal Tumor) 01/2004
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2004
1	Melanoma (Melanoma, Malignant) 01/2004

Drug/Important Bio-Agent (IBA)

5	FructoseIBA 01/2021 - 08/2005
5	Insulin (Novolin)FDA Link 01/2021 - 09/2006
5	Phosphotransferases (Kinase)IBA 01/2021 - 08/2005
5	Phosphofructokinase-2 (Phosphofructokinase 2)IBA 01/2021 - 02/2010
4	CytokinesIBA 01/2021 - 03/2016
4	EnzymesIBA 01/2021 - 06/2012
3	Choline (Choline Chloride)IBA 01/2022 - 09/2019
3	Methionine (L-Methionine)FDA Link 01/2022 - 09/2019
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 12/2018
3	Adenosine (Adenocard)FDA LinkGeneric 09/2019 - 01/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 09/2006
2	indoleIBA 01/2022 - 10/2020
2	InterleukinsIBA 01/2021 - 12/2018
2	LipopolysaccharidesIBA 01/2021 - 12/2018
2	Messenger RNA (mRNA)IBA 09/2019 - 03/2016
2	JNK Mitogen-Activated Protein KinasesIBA 09/2019 - 12/2018
2	vadimezanIBA 12/2018 - 01/2017
2	cyclic guanosine monophosphate-adenosine monophosphateIBA 12/2018 - 01/2017
2	Interferon Type IIBA 12/2018 - 01/2017
2	Metformin (Glucophage)FDA LinkGeneric 01/2017 - 01/2014
2	AMP-Activated Protein KinasesIBA 03/2016 - 12/2012
1	XIST non-coding RNAIBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	Long Noncoding RNAIBA 01/2021
1	Toll-Like Receptor 4IBA 01/2021
1	bcl-2-Associated X Protein (bcl 2 Associated X Protein)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 09/2019
1	NF-kappa B (NF-kB)IBA 09/2019
1	Interleukin-1beta (Interleukin 1 beta)IBA 09/2019
1	Proteins (Proteins, Gene)FDA Link 12/2018
1	EndotoxinsIBA 01/2018
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2017
1	BerberineIBA 03/2016
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2013
1	PhosphoenolpyruvateIBA 04/2013
1	LipidsIBA 12/2012
1	palmitoleic acidIBA 01/2012
1	Rosiglitazone (Avandia)FDA Link 07/2010
1	PPAR gammaIBA 07/2010
1	Neuropeptide YIBA 08/2005
1	Protein Isoforms (Isoforms)IBA 01/2004

Therapy/Procedure

2	Transplantation 12/2018 - 06/2012
1	Otoscopes 01/2021